TKTakayuki Kondo

Takayuki Kondo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takayuki Kondo has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Chihiro Fujii

    Department of Neurology, Kansai Medical University Medical Center, Osaka, Japan

    6 shared publications
  • Ryosuke Takahashi

    Kyoto University Research Administration Center, Kyoto, Japan

    6 shared publications
  • Mio Hamatani

    Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    5 shared publications
  • Shinji Ashida

    Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan

    5 shared publications
  • Hirofumi Ochi

    Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime, Japan

    4 shared publications
  • Kazuyuki Kawamura

    Department of Neurology, National Hospital Organization Minami Kyoto Hospital, Kyoto, Japan

    4 shared publications

Latest Publications

  • Open Access

    Beyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis

    by Yuriko Aratake, Kenji Yoshinaga, Shinji Ashida, Chihiro Fujii, Mio Hamatani, Kimitoshi Kimura, Hirofumi Ochi, Ryosuke Takahashi, Takayuki Kondo

    Background: Revisions of the McDonald diagnostic criteria have improved the sensitivity of multiple sclerosis (MS) diagnosis by incorporating MRI-based dissemination in space and time. However, some inflammatory demyelinating lesions fulfill dissemination criteria while showing radiological features atypical for MS, even in the absence of anti-AQP4 and anti-MOG antibodies. The long-term radiological course of these atypical idiopathic inflammatory demyelinating lesions (AIIDLs) remains unclear. Methods: We retrospectively analyzed 39 Japanese patients with AIIDLs, classified into multiple spotty lesions (MSLs), disseminated encephalomyelitis-like lesions (DEMLs), leukoencephalopathy-like lesions (LELs), and tumefactive lesions (TLs), and compared them with 97 patients with radiologically typical MS. Longitudinal MRI analyses evaluated lesion morphology, distribution, volume, and central vein sign (CVS) positivity, together with clinical outcomes and treatment responses. Results: Over a mean follow-up of 11 years, 38 of 39 AIIDL cases (97.4%) retained radiologically atypical features despite clinical relapses and fulfillment of dissemination criteria. MSLs and TLs lacked canonical MS features, such as periventricular lesions and T1 hypointense black holes. Only one case with LELs evolved into typical MS. CVS positivity exceeding 40% was observed in two MSLs cases but lesions remained atypical in distribution. Lesion volumes differed significantly among subgroups, with smaller volumes in MSLs and larger volumes in LELs compared with typical MS. Corticosteroids, immunosuppressants, and B cell depletion therapies appeared to be associated with clinical stabilization in several AIIDL subtypes, whereas conventional MS disease-modifying therapies were less consistently effective. Conclusions: In this cohort, most AIIDLs retained radiologically atypical brain MRI features over long-term follow-up despite recurrent inflammatory demyelinating events. These findings suggest that dissemination-based criteria alone may not fully capture the radiological heterogeneity of AQP4-IgG- and MOG-IgG-negative demyelinating disorders. Longitudinal lesion-based MRI phenotyping may provide complementary information for diagnostic reassessment although external validation and integration with optic nerve, spinal cord, and biological markers are required.

  • Open Access

    Immunological role of sulfatide in the pathogenesis of multiple sclerosis

    by Mio Hamatani, Takayuki Kondo

    An abstract is unavailable. This article is available as a PDF only.


  • T cells from MS Patients with High Disease Severity Are Insensitive to an Immune-Suppressive Effect of Sulfatide

    by Mio Hamatani, Hirofumi Ochi, Kimitoshi Kimura, Shinji Ashida, Yuichiro Hashi, Yoichiro Okada, Chihiro Fujii, Kazuyuki Kawamura, Toshiki Mizuno, Hideki Ueno, et al.

    Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Its early phase is characterized by a relapse-remitting disease course, followed by disability progression in the later stage. While chronic inflammation accompanied with degeneration is well-established as the key pathological feature, the pathogenesis of MS, particularly progressive MS, remains elusive. Sulfatide is a major glycolipid component of myelin, and previous studies in experimental autoimmune encephalomyelitis mouse models have demonstrated it to have immune-protective functions. Notably, sulfatide concentration is increased in the serum and cerebrospinal fluid of patients with MS, particularly those in a progressive disease course. Here, we show that the myelin-glycolipid sulfatide displays an ability to suppress the proliferation of polyclonally activated human T cells. Importantly, this suppressive effect was impaired in T cells obtained from MS patients having higher disability status. Therefore, it is plausible that progression of MS is associated with an escape from the immune-regulatory effect of sulfatide. Our study suggests that, although the precise mechanisms remain unrevealed, an escape of T cells from immunosuppression by sulfatide is associated with disease progression in the advanced stage. Further studies will provide novel insights into the pathogenesis of MS, particularly regarding disease progression, and help develop novel treatment strategies for this challenging disease.


  • Open Access

    Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan

    by Shinji Ashida, Hirofumi Ochi, Mio Hamatani, Chihiro Fujii, Ryusei Nishigori, Kazuyuki Kawamura, Sadayuki Matsumoto, Masanori Nakagawa, Ryosuke Takahashi, Toshiki Mizuno, et al.

    Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of central nervous system showing marked clinical heterogeneity. Many factors might influence the choice of relapse prevention drug, and treatment response varies among patients. Despite the enlargement of disease-modifying drugs for MS (MS-DMDs), some patients have been treated with corticosteroid and/or immunosuppressant (CS/IS).Objective: To clarify the radiological and laboratory features of MS treated with CS/IS for relapse prevention.Methods: Clinical records including radiological and laboratory findings, and drugs used for relapse prevention were reviewed retrospectively.Results: Out of 92 consecutive MS patients, 25 (27%) were treated with CS/IS. The followings were observed less frequently in patients treated with CS/IS than in those with MS-DMDs: three or more periventricular lesions, ovoid lesions, subcortical lesions, typical contrast-enhancing lesions, negative for serum autoantibodies, and positive for oligoclonal bands in the cerebrospinal fluid. Multiple logistic regression analysis revealed that the absence of typical contrast-enhancing lesions and positivity for serum autoantibodies were independent factors associated with CS/IS prescription (odds ratio 25.027 and 14.537, respectively).Conclusion: In this cohort of Japanese patients clinically diagnosed with MS, radiological and serological findings atypical of MS were observed more frequently in patients treated with CS/IS than in those with MS-DMDs as a part of MS therapy. The absence of contrast-enhancing lesions typical of MS and positivity for serum autoantibodies were independent factors strongly associated with CS/IS use.


  • Open Access

    Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity

    by Shinji Ashida, Hirofumi Ochi, Mio Hamatani, Chihiro Fujii, Kimitoshi Kimura, Yoichiro Okada, Yuichiro Hashi, Kazuyuki Kawamura, Hideki Ueno, Ryosuke Takahashi, et al.

    Objective To clarify functional alterations of follicular helper T cells (Tfh) in myasthenia gravis (MG) because Tfh play important roles in helping B cells generate antibody-producing cells. Methods A total of 24 immunotherapy-naive patients with anti–acetylcholine receptor (AchR) antibody–positive MG and 18 age-matched healthy subjects (HS) were enrolled. Samples from 6 patients were available for posttreatment analysis. Subsets of circulating Tfh (cTfh) and B cells were identified by flow cytometry analysis of surface molecules. Cytokine production by isolated cTfh subsets from 5 patients with MG and 5 HS was measured in vitro. Analysis was performed to examine the correlation between the frequency of cTfh subsets and that of plasmablasts and between cTfh subsets and the quantitative MG score. Results cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOShighcTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOSlow cTfh only in patients with MG. The frequency of cTfh within CD4 T cells was more closely associated with disease severity than the serum anti-AchR antibody titer and frequency of plasmablasts within B cells. Abnormalities of cTfh were improved after immunotherapy in parallel with clinical improvement. Conclusions Alternation of cTfh is a key feature in the development of MG and may become a biomarker for disease severity and therapeutic efficacy. Classification of Evidence This study provides Class II evidence that the level of cTfh is associated with disease severity in patients with MG.


  • Open Access

    Altered features of monocytes in adult onset leukoencephalopathy with axonal spheroids and pigmented glia: A clue to the pathomechanism of microglial dyshomeostasis

    by Mio Hamatani, Hirofumi Yamashita, Hirofumi Ochi, Shinji Ashida, Yuichiro Hashi, Yoichiro Okada, Chihiro Fujii, Kazuyuki Kawamura, Riko Kitazawa, Masanori Nakagawa, et al.


  • Open Access

    A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries

    by Takahiko Saida, Takashi Yamamura, Takayuki Kondo, Jang Yun, Minhua Yang, Jie Li, Lalitha Mahadavan, Bing Zhu, Sarah I. Sheikh

    Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety outcomes of DMF in a predominantly East Asian population of patients with RRMS. In this 24-week, randomized, double-blind, placebo-controlled phase 3 study, 225 patients, 142 of which were East Asian (63.4%), were enrolled: Japan (n = 114), South Korea (n = 20), Taiwan (n = 8), the Czech Republic (n = 42), and Poland (n = 40). Key exclusion criteria included diagnosis of neuromyelitis optica spectrum disorder. Stratified by country, patients were randomized 1:1 to receive DMF 240 mg twice daily or placebo. Clinical assessments, including neurological examination and EDSS scoring, were conducted at baseline and at weeks 12 and 24. A total of 213 patients (95.1%) completed the study. From weeks 12 – 24, the total number of new gadolinium-enhancing (Gd+) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo. For the secondary endpoint, from baseline to week 24, the total number of new Gd+ lesions was reduced by 75% and the mean number of new/newly enlarging T2 hyperintense lesions was reduced by 63% (both p < 0.0001). Flushing and flushing-related symptoms, and gastrointestinal events were adverse events related to DMF treatment. Efficacy and safety results in the Japanese subgroup and the East Asian subgroup (which included patients from Japan, Taiwan, and South Korea) were consistent with the overall study population. The strong efficacy and favorable benefit-risk profile of DMF extends to Japanese, and more broadly, East Asian patients with RRMS. This trial is registered on ClinicalTrials.gov (identifier: NCT01838668 ), April 20, 2013 (retrospectively registered). The registration can be found at the following URL: https://clinicaltrials.gov/ct2/show/NCT01838668


  • Signaling via toll-like receptor 4 and CD40 in B cells plays a regulatory role in the pathogenesis of multiple sclerosis through interleukin-10 production

    by Yoichiro Okada, Hirofumi Ochi, Chihiro Fujii, Yuichiro Hashi, Mio Hamatani, Shinji Ashida, Kazuyuki Kawamura, Hirofumi Kusaka, Sadayuki Matsumoto, Masanori Nakagawa, et al.


  • Open Access

    Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy

    by Chihiro Fujii, Takayuki Kondo, Hirofumi Ochi, Yoichiro Okada, Yuichiro Hashi, Tetsuya Adachi, Masaharu Shin-Ya, Sadayuki Matsumoto, Ryosuke Takahashi, Masanori Nakagawa, et al.

    Multiple sclerosis (MS) is a T cell-mediated autoimmune disease. Fingolimod, a highly effective disease-modifying drug for MS, retains CCR7+ central memory T cells in which autoaggressive T cells putatively exist, in secondary lymphoid organs, although relapse may still occur in some patients. Here, we analyzed the T cell phenotypes of fingolimod-treated, fingolimod-untreated patients, and healthy subjects. The frequency of CD56+ T cells and granzyme B-, perforin-, and Fas ligand-positive T cells significantly increased during fingolimod treatment. Each T cell subpopulation further increased during relapse. Interestingly, T cells from fingolimod-treated patients exhibited interferon-γ biased production, and more myelin basic protein-reactive cells was noted in CD56+ than in CD56− T cells. It is likely that the altered T cell phenotypes play a role in MS relapse in fingolimod-treated patients. Further clinical studies are necessary to investigate whether altered T cell phenotypes are a biomarker for relapse under fingolimod therapy.


  • Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders

    by Mitsuru Watanabe, Takayuki Kondo, Kenji Murakata, Takashi Kageyama, Yoko Shibata, Toshiyuki Takahashi, Kyoichi Nomura, Sadayuki Matsumoto